Epitopea Doses First Patient in Phase 1/1b Trial for Advanced Ovarian Cancer
Event summary
- First patient dosed in OVACT Phase 1/1b trial of CryptiVax™-1001 for advanced high-grade serous ovarian cancer (HGSOC).
- Trial will enroll up to 30 patients across 10 UK clinical centers.
- CryptiVax™-1001 targets HRP+/BRCA-wildtype HGSOC, an underserved patient population.
- Epitopea's CryptoMap™ platform identifies novel tumor-specific antigens from the 'dark genome'.
- Trial led by Professor Susana Banerjee of The Royal Marsden and ICR.
The big picture
Epitopea's trial initiation highlights the growing focus on RNA-based immunotherapies for solid tumors, particularly in indications with limited durable treatment options. The company's CryptoMap™ platform represents a novel approach to identifying tumor-specific antigens, potentially expanding the reach of personalized cancer vaccines. Success in this trial could validate Epitopea's technology and position it as a key player in the oncology immunotherapy space.
What we're watching
- Clinical Efficacy
- Whether CryptiVax™-1001 demonstrates meaningful durable responses in HRP+/BRCA-wildtype HGSOC patients.
- Regulatory Pathway
- The pace at which Epitopea advances through clinical phases given the trial's design and patient population.
- Competitive Positioning
- How Epitopea's off-the-shelf RNA vaccine approach differentiates it in the crowded ovarian cancer treatment landscape.
Related topics
